HUMAN MICROBIOME MARKET ANALYSIS

Human Microbiome Market, By Product Type [Food (Probiotics, Prebiotics, Medical Food Supplements, Others (Symbiotic, Antibiotics, etc.)), Microbome Drugs, Fecal Microbiota Transplant], By Application [Therapeutics, Diagnostics, Nutrition and Deities, Others (Cosmetics, Animal health etc.)], By Disease Indication (Auto Immune Disorder, Clostridium Difficile Infection, Metabolic Disorder, Inflammatory Bowel disorder, Infectious Diseases, and Others (Cancer, Rare Diseases), By Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies), and By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Sep 2023
Code : CMI182
Pages :180
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global Human Microbiome Market: Key Developments

In April 2023, MaaTpharma, a clinical stage microbiome therapeutics company, recieved the U.S. Food and Drugs Administration (FDA) approval to proceed with phase III trial of ‘MaaT013’ drug indicated to treat gastrointestinal acute graft-versus-host disease (aGvHD) as a third line of treatment
In June 2020, Enterome SA, a clinical-stage biopharmaceutical company with development of microbiome-immunoinflammation, financed totaling US$ 52.6 million to develop and progress the clinical development of therapeutic pipeline, and clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy
In May 2022, 4D Pharma, a global pharmaceutical company that develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis, announced clinical trial for MRx0518 with combination bavencio, a PD – L1 blocking antibody indicated for the treatment of urothelial cancer
On January 16, 2023, Genetic Analysis AS, a research driven diagnostic company that focuses on innovative diagnostic solutions with microbiota analysis, entered into an agreement with Microbiome Research Pvt. Ltd., a India-based microbiome company, for launching a test service portfolio based on the GA-map Dysbiosis Test, and thus, making it the first CE-IVD marked standardized gut microbiome test.
In March 2022, EnteroBiotix Limited, a clinical stage biotechnology company, announced the initation of phase II clinical trial of EBX-102, an orally administered capsule that is indicated to treat liver cirrhosis and hepatic encephalopathy.

Global Human Microbiome Market: Key Trends

Introduction of Human Microbiome with advanced technology of next gen sequencing: The human microgenomics research and development got drived with the introduction of technical advancement like metagenomics and next gen sequencing which gave opportunity for the microbiome market to unravel the human microbiome and analyze its role associated health, beauty and disease by “Human Microbiome Project”.For instance, National Institute of Health started ‘the Human Microbiome Project (HMP)’ in 2007 wih the goal of identifying and characterizing the microorganisms found in association with both healthy and diseased humans and the National Microbiome. This initiative accelerated research on the human microbiome was initiated by the U.S. government. The field of the human microbiome was funded by $115 million by the U.S. government. By the end of year 2017, HMP investigators published over 650 scientific papers which is cited 70,000 times as of today.